丙泊酚
医学
非典型溶血尿毒综合征
单克隆抗体
免疫学
疾病
替代补体途径
抗体
补体系统
肾
溶血-尿毒症性综合征
肾脏疾病
单克隆
纤维蛋白原
病理
补体成分5
透析
蛋白尿
发病机制
表位
伊库利珠单抗
病态的
微血管病性溶血性贫血
作者
Grace Mallett,Ola Kamala,Isabel Y. Pappworth,Kate Smith‐Jackson,Beth G. Gibson,Muhammad Asif,Harriet Denton,Charlotte Cox,Patrick R. Walsh,David Kavanagh,Kevin J. Marchbank
标识
DOI:10.3389/fimmu.2026.1828298
摘要
Introduction: We have previously shown that the C3D1115N mouse, engineered around a single point mutation in C3 associated with atypical haemolytic uraemic syndrome (aHUS) in man, fully recapitulates the clinical disease. In this study, we investigated the role of properdin in aHUS. Methods: C3D1115N mice were crossed onto properdin-deficient mice or C3D1115N mice were treated with anti-properdin monoclonal antibody therapy and survival tracked. Kidney function, serum biomarkers and kidney pathology was carefully assessed at set end points. C3 and Fibrin deposition was assessed using immuno-fluorescence. Results: We have found that removing properdin ameliorates disease, although two mice had evidence of renal disease over a ~6-month period. Therapeutic treatment with an anti-properdin monoclonal antibody (14E1) after evidence of clinical disease was sufficient to block the progression of disease, suggesting that measures to reduce the stability of the alternative pathway C3 and C5 convertases can help prevent thrombotic microangiopathic anaemia (TMA)/aHUS. Discussion: Our data indicate that a fine balance exists between disease progression and resolution in our C3 gain-of-function model. The data also suggest that anti-properdin therapy, as noted in another mouse model of TMA, may provide a viable treatment option to maintain remission in complement mediated aHUS.
科研通智能强力驱动
Strongly Powered by AbleSci AI